Novartis Stock Forecast, Price & News

Novartis' stock was trading at $82.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVS shares have increased by 16.8% and is now trading at $95.94.
View which stocks have been most impacted by COVID-19.

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novartis stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View analyst ratings for Novartis or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Novartis a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Novartis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

938 employees have rated Novartis CEO Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among Novartis' employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Novartis is scheduled to release its next quarterly earnings announcement on Tuesday, January 26th 2021.
View our earnings forecast for Novartis.

Novartis AG (NYSE:NVS) announced its quarterly earnings results on Tuesday, January, 26th. The company reported $1.34 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.37 by $0.03. The company earned $12.77 billion during the quarter, compared to the consensus estimate of $12.86 billion. Novartis had a net margin of 14.71% and a trailing twelve-month return on equity of 24.39%. The business's revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.32 earnings per share.
View Novartis' earnings history.

Novartis declared an annual dividend on Monday, February 3rd. Investors of record on Wednesday, March 4th will be paid a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is a positive change from Novartis's previous annual dividend of $2.86.
View Novartis' dividend history.

Novartis pays an annual dividend of $2.01 per share and currently has a dividend yield of 2.04%. The dividend payout ratio of Novartis is 38.36%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novartis will have a dividend payout ratio of 30.83% next year. This indicates that Novartis will be able to sustain or increase its dividend.
View Novartis' dividend history.

10 brokers have issued 12-month price targets for Novartis' stock. Their forecasts range from $112.00 to $116.00. On average, they anticipate Novartis' share price to reach $114.00 in the next year. This suggests a possible upside of 18.8% from the stock's current price.
View analysts' price targets for Novartis or view Wall Street analyst' top-rated stocks.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche (RHHBY), Pfizer (PFE), Eli Lilly and (LLY), Abbott Laboratories (ABT), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), GlaxoSmithKline (GSK), CSL (CSLLY), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
View all of NVS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), The Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis' stock is owned by many different retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.09%), Schafer Cullen Capital Management Inc (0.09%), Scharf Investments LLC (0.05%), Douglas Lane & Associates LLC (0.03%), Cullen Capital Management LLC (0.02%) and Welch Group LLC (0.02%).

NVS stock was sold by a variety of institutional investors in the last quarter, including Schafer Cullen Capital Management Inc, Cullen Capital Management LLC, Manning & Napier Group LLC, Scharf Investments LLC, Transform Wealth LLC, Scout Investments Inc., Clark Capital Management Group Inc., and Grassi Investment Management.

NVS stock was purchased by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Douglas Lane & Associates LLC, Pacer Advisors Inc., TIAA FSB, Cardinal Capital Management Inc., Kestra Private Wealth Services LLC, FNY Investment Advisers LLC, and Altfest L J & Co. Inc..

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $95.94.

Novartis has a market capitalization of $219.58 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 110,000 workers across the globe.

The official website for Novartis is www.novartis.com.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]